Tissue Regenix (TRX): 2018 in review: foundatio...

Hardman & Co Research Hardman & Co Research: Tissue Regenix (TRX): 2018 in review: foundations laid for osteobiologics 17-Dec-2018 / 11:56 GMT/BST Hardman & Co: 2018 in review: foundations laid for osteobiologics TRX has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for the repair of soft tissue (dCELL) and bone (BioRinse). With organic growth being boosted by the acquisition of CellRight Technologies, 2017 was a dynamic year for TRX. As part of the integration, management embarked upon a revised commercial strategy to increase sales momentum and market penetration in 2018. Having already signed an agreement with Arthrex for the US, TRX has now entered a distribution agreement with Arthrex in Europe. Please click here for the full report: https://www.hardmanandco.com/research/corporate-research/2018-in-review-foundations-laid-for-osteobiologics/ To contact us: Hardman & Co 35 New Broad Street London EC2M 1NH www.hardmanandco.com Follow us on Twitter @HardmanandCo Contacts: Dr Martin Hall Dr Dorothea Hill Dr Gregoire Pave [phone] [e-mail] [e-mail] [e-mail]   Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement. About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services. Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer. Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

End of Announcement - EQS News Service

758887  17-Dec-2018